ADGRA2

Across TCGA pan-cancer cohorts, ADGRA2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ADGRA2 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher ADGRA2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADGRA2 expression acts as an unfavorable survival marker, although some lineages such as STAD and LUSC show a favorable association.

KIRP, OV, and STAD are the cancer types where ADGRA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	II,III,IV	0.037	0.783	<.001	18	view →
OV	OS	Median	IV	0.028	0.759	.002	12	view →
STAD	DFS	Median	All	1.000	0.338	.034	7	view →
PRAD	DFS	Median	All	0.449	0.888	<.001	6	view →
LUSC	DFS	Median	All	1.000	0.740	.041	4	view →
ESCA	DFS	Median	All	0.192	0.535	.037	3	view →
SCLC	DFS	Median	All	1.000	0.264	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ADGRA2–KIRP (DFS)

Open the KIRP breakdown →